Advisory Services
GCC & MENA Pharmaceutical M&A Advisory — Saudi Arabia, Gulf Region, and Wider MENA
PharmaBoard Advisory provides specialist M&A and commercial strategy services exclusively for the pharmaceutical, nutraceutical, and cosmeceutical sectors. Every engagement is scoped individually — contact us to discuss your specific situation.
M&A Deal Advisory
Buy-side and sell-side pharmaceutical transaction support across Saudi Arabia and the GCC.
We act as your deal intermediary — identifying targets, structuring transactions, and managing the process from first conversation to close.
→ Acquisition target screening and identification
→ Deal structuring — acquisition, JV, licensing, or partnership
→ Management of introduction and negotiation process
→ Coordination with legal and financial advisors through closing
Commercial Due Diligence
Pre-acquisition asset validation designed specifically for GCC pharma deals.
We assess what global CDD templates miss — NUPCO concentration risk, SFDA regulatory exposure, key-person dependency, and localization scoring.
→ NUPCO procurement concentration analysis
→ SFDA registration pipeline review
→ Key-person commercial dependency mapping
→ Distribution agreement transferability assessment
→ Final CDD report and executive presentation
Market Entry & Commercial Strategy
Market intelligence and entry strategy for Saudi Arabia and the GCC.
For international pharma companies and investors who need ground-truth intelligence before committing to a transaction or commercial expansion.
→ Saudi Arabia and GCC pharmaceutical market assessment
→ Optimal market entry model design
→ NUPCO tender strategy and localization roadmap
→ Distributor identification and governance framework
→ SFDA regulatory pathway planning
Post-Merger Integration (PMI) Support
Integration support for MENA pharma transactions.
Value is not created at the signing table — it is protected or lost in the first 100 days after closing. We help acquirers plan and govern that period so the commercial value of the deal is retained.
→ Government and NUPCO relationship continuity
→ Commercial team alignment and distributor rationalization
→ SFDA regulatory transfer planning
→ Integration governance and synergy tracking
Commercial Feasibility & Launch Strategy
Business planning for pharma, nutraceutical, and cosmeceutical ventures in MENA.
A poorly built plan at this stage costs companies years and millions in wasted capital. We build the commercial blueprint before you commit.
→ Market sizing and regulatory pathway analysis
→ Business model design and financial projections
→ Go-to-market strategy and channel selection
→ Risk register with mitigation plan
→ Investor-ready business plan and presentation deck